Literature DB >> 22150825

Improving the flexibility and efficiency of phase II designs for oncology trials.

Stefan Englert1, Meinhard Kieser.   

Abstract

Phase II trials in oncology are usually conducted as single-arm two-stage designs with binary endpoints. Currently available adaptive design methods are tailored to comparative studies with continuous test statistics. Direct transfer of these methods to discrete test statistics results in conservative procedures and, therefore, in a loss in power. We propose a method based on the conditional error function principle that directly accounts for the discreteness of the outcome. It is shown how application of the method can be used to construct new phase II designs that are more efficient as compared to currently applied designs and that allow flexible mid-course design modifications. The proposed method is illustrated with a variety of frequently used phase II designs.
© 2011, The International Biometric Society.

Mesh:

Year:  2011        PMID: 22150825     DOI: 10.1111/j.1541-0420.2011.01720.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  5 in total

1.  Stopping for efficacy in single-arm phase II clinical trials.

Authors:  Rezoanoor Rahman; M Iftakhar Alam
Journal:  J Appl Stat       Date:  2021-03-21       Impact factor: 1.416

2.  Optimal adaptive two-stage designs for early phase II clinical trials.

Authors:  Guogen Shan; Gregory E Wilding; Alan D Hutson; Shawn Gerstenberger
Journal:  Stat Med       Date:  2015-11-03       Impact factor: 2.373

3.  Phase I/II trial evaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: the PANDORA-01 trial.

Authors:  Stephanie E Combs; Meinhard Kieser; Daniel Habermehl; Jürgen Weitz; Dirk Jäger; Piero Fossati; Roberto Orrechia; Rita Engenhart-Cabillic; Richard Pötter; Manjit Dosanjh; Oliver Jäkel; Markus W Büchler; Jürgen Debus
Journal:  BMC Cancer       Date:  2012-04-03       Impact factor: 4.430

4.  Minimax and admissible adaptive two-stage designs in phase II clinical trials.

Authors:  Guogen Shan; Hua Zhang; Tao Jiang
Journal:  BMC Med Res Methodol       Date:  2016-08-02       Impact factor: 4.615

5.  Re-formulating Gehan's design as a flexible two-stage single-arm trial.

Authors:  Michael J Grayling; Adrian P Mander
Journal:  BMC Med Res Methodol       Date:  2019-01-28       Impact factor: 4.615

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.